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Opinion statement
Acute brain ischemia is a dynamic process susceptible to multiple modulating factors,
such as blood glucose level. During acute ischemic brain injury, hyperglycemia exacer-
bates multiple deleterious derangements. Timely and sufficient correction of hyperglyce-
mia during acute brain ischemia may limit the brain injury and improve clinical
outcomes. The clinical efficacy of such intervention remains to be proven. Although
results from animal and clinical observational studies suggest that hyperglycemia during
acute brain ischemia may exacerbate the brain injury, there is no evidence from random-
ized treatment trials that rapid correction of the hyperglycemia improves outcomes. Giv-
en the excess effort, cost, and risk involved in rapid and safe correction of hyperglycemia
during acute stroke, less aggressive treatments with subcutaneous insulin seem appropri-
ate at this time. Subcutaneous insulin protocols can maintain blood glucose levels below
200 mg/dL a majority of the time in most patients, especially if basal insulin is added.
When available, an endocrinology consultant can optimize the acute treatment and help
the transition to long-term care. Given the multiple reports linking admission hypergly-
cemia with symptomatic hemorrhagic conversion of ischemic stroke treated with throm-
bolytic drugs, it may be best to rapidly lower severe hyperglycemia in such patients. For
example, if the admission blood glucose is approximately 300 mg/dL and the patient is a
candidate for thrombolytic therapy, consider giving an intravenous bolus of regular in-
sulin 8 units. Somewhat lower or higher insulin doses may be best for lesser or greater
hyperglycemia. Such a bolus will start lowering the blood glucose in about 5 min. A tem-
porary continuous intravenous insulin infusion may then be used in most patients to
maintain the glucose closer to normal levels (eg, below 180 or 140 mg/dL).Introduction
Blood glucose regulation involves intestinal absorp-
tion, release into the bloodstream from glycogen
stores (glycogenolysis), synthesis (gluconeogenesis)
and release into the bloodstream, transport from
blood into interstitial spaces and cells throughout
the body, and urinary excretion. Levels of blood glu-
cose fluctuate more rapidly and to a greater extent
than levels of any other metabolite. Such glucose fluc-
tuations are greater in patients with insulin resistance
and during acute illness. Either excessively low or high
blood glucose levels have well-known complications.
This review focuses on hyperglycemia.
Although the complications of chronic hypergly-
cemia and acute hyperosmolar severe hyperglycemia
are well known, the complications of acute (stress)
moderate hyperglycemia are not. Approximately
40% of patients with acute ischemic stroke have
admission hyperglycemia (9130 mg/dL) [1,2], and
the majority of such patients have diabetes mellitus.
The hyperglycemia during acute stroke reflects both
a spectrum of acute stress and a spectrum of insulin
resistance. Our ability to correct glucose deviations
rapidly may have important clinical implications
in patients with acute ischemic stroke. Here we sum-
marize the data about hyperglycemia during acute
ischemic stroke and how it relates to outcomes.
We also offer suggestions for treating hyperglycemia
during acute stroke.
Diabetes and risk of stroke
Diabetes mellitus, through chronic hyperglycemia, has been linked with ac-
celerated development of both microvascular disease and atherosclerosis
throughout the body. Consequently, diabetes mellitus increases the com-
bined risk of stroke and myocardial infarction by about 2.5 times [3]a n d
the risk of stroke alone 1.7 to 2.1 times [4,5], compared with otherwise sim-
ilar patients without diabetes. Diabetes also increases the risk of stroke after a
transient ischemic attack (TIA), as it represents one of the Ds in the ABCD
2
score, which includes age (0 or 1), blood pressure level (0 or 1), clinical
stroke symptoms (0, 1, or 2), duration of the TIA symptoms (0, 1, or 2),
and diabetes (0 or 1) [6]. Risk of stroke increases with increasing ABCD
2
score, within the range from 0 to 7.
Thus it is reasonable to expect that better control of chronic hyperglyce-
mia may reduce the incidence of vascular events. This hypothesis was tested
in five randomized clinical trials totaling 33,040 patients: strict glycemic con-
trol lowered the hemoglobin A1C by 0.9% (from 7.5% to 6.6%) compared
with standard therapy [7]. In these five clinical trials, strict glycemic control
lowered the rate of coronary events, but not stroke or death. A reason for
these findings is not readily apparent.
Elevated fasting glucose or diabetes mellitus in combination with other,
interrelated vascular risk factors has been defined as the metabolic syndrome
[8]. Because of the coexistence of multiple vascular risk factors, patients with
the metabolic syndrome have a higher risk for vascular outcomes than those
with a single risk factor. The International Diabetes Federation has defined
the metabolic syndrome as central obesity plus two of the following four ad-
ditional derangements: 1) elevated triglycerides, 2) decreased HDL cholester-
ol, 3) elevated blood pressure, and 4) elevated fasting plasma glucose. Thus,
although all patients with the metabolic syndrome have central obesity, they
are somewhat heterogeneous with respect to the other risk factors. Conse-
quently, treatment for the metabolic syndrome is individualized and not
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syndrome should be identified and treated as indicated, and that classifica-
tion into this syndrome offers no clear advantage.
Can animal stroke hyperglycemia studies lead to optimized
clinical trials?
Although animal studies usually precede clinical trials, there is a risk that
positive findings in animals will not translate to similar clinical results
[9]. In most animal studies, acute hyperglycemia immediately before or
during ischemia exacerbates the ischemic brain injury [10–13]. Compared
with normoglycemic animals, animals with ischemic stroke and hyperglyce-
mia tend to have more brain edema, hemorrhagic transformation of
infarcts, brain herniation, and death. However, not all animal studies con-
firm such observations. The exacerbated damage with hyperglycemia is usu-
ally seen in animal ischemic stroke models with reperfusion and occurs less
with permanent occlusion [12,14]. This finding suggests that reperfusion of
ischemic brain may be an important factor leading to increased brain damage
by hyperglycemia [13].
Relatively few animal interventional studies have looked at the effects of
hyperglycemia correction in focal brain ischemia [11,15–17]. Some animal
interventional studies show a benefit related to reduction of the acute hyper-
glycemia. Unfortunately, many of the animal studies do not seem clinically
relevant because the models involved global and not focal brain ischemia,
the glucose levels were unusually high, or the hyperglycemia was corrected
around the time that the ischemia began. In some studies using insulin,
the animals became severely hypoglycemic (G45 mg/dL), had seizures, and
died. One such study reported a U-shaped curve indicating optimal outcome
at a glucose level of about 126 mg/dL and worsening outcomes below and
above this level [17].
In an acute ischemic stroke interventional study in rats, one group of 10
rats was made hyperglycemic (555 mg/dL) for 2 h before and 2 h after per-
manent middle cerebral artery (MCA) occlusion, another group of ten was
made diabetic (blood glucose, 542 mg/dL) 4 days before the MCA occlusion
and was not treated, another group of ten was made diabetic and was treated
with insulin since 2 days before the MCA occlusion (blood glucose, 176 mg/
dL), and 15 rats were used as controls (blood glucose, 156–176 mg/dL) [15].
Infarct volumes were larger with acute hyperglycemia (161 mm
3)a n dw i t h
untreated diabetes (190 mm
3) than with insulin-treated diabetes
(131 mm
3) or in controls (121 mm
3). However, a therapeutic effect cannot
be translated to clinical acute stroke, as insulin treatment was started 2 days
before the MCA occlusion, and blood glucose levels at the time of MCA oc-
clusion were similar to those in the control group.
Unfortunately, the animal studies so far have not established a clear
relation between the degree of hyperglycemia and extent of acute ischemic
brain injury. Is the relationship linear, as suggested by some clinical stud-
ies? Also, a therapeutic time window for hyperglycemia correction has
not been established. Is it crucial (as with thrombolytic therapies) to inter-
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window extend?
Can nonstroke acute hyperglycemia correction clinical trials
be extrapolated to stroke?
Randomized trials have studied aggressive correction of hyperglycemia in
multiple acute illnesses, with varied results. The most convincing positive tri-
al was the surgical intensive care unit (SICU) trial, in which postsurgical ven-
tilated patients were randomized to aggressive or standard correction of
hyperglycemia while in the SICU [18, Class I]. Patients treated aggressively
had considerably lower mean glucose levels (by about 50 mg/dL) and better
clinical outcomes than patients under standard care. Significant benefits
associated with aggressive hyperglycemia correction included decreased mor-
tality, shorter time on ventilator, fewer bloodstream infections, and less
critical-illness polyneuropathy. A similar trial with patients in the medical in-
t e n s i v ec a r eu n i t( M I C U )s h o w e dl e s sc o n v i ncing results, without a statistically
significant difference in the primary outcome (mortality) [19,C l a s sI ] .H o w e v e r ,
mortality among patients who stayed in the MICU for at least 3 days (secondary
outcome) was significantly reduced in the aggressive insulin treatment group.
The mean blood glucose difference between the treatment groups in that trial
was about 51 mg/dL.
In the latest ICU trial of hyperglycemia correction, 6104 patients were ran-
domized to intensive or standard treatment for three or more days [20, Class
I]. The mean blood glucose was about 35 mg/dL lower in the intensive group
than in the standard group. The primary outcome, death, was more common
in the intensive treatment group (27.5%) than in the standard treatment
group (24.9%; P=0.02). This treatment effect was similar among medical
and surgical ICU patients. Severe hypoglycemia (G40 mg/dL) occurred in
6.8% of patients in the intensive group and 0.5% of those in the standard
group.
One trial tested the efficacy of aggressive hyperglycemia correction in
patients with sepsis [21]. The mean glucose levels were 39 mg/dL lower in
the aggressive-treatment group than in the usual-care group. That trial was
stopped early because of safety concerns about excess severe hypoglycemia
(G40 mg/dL) in the aggressive-treatment group (17.0% vs 4.1% in the con-
trol group). The severe hypoglycemia in the aggressively treated group was
associated with a significantly higher rate of serious adverse events (10.9%
vs 5.2% in the control group).
Three randomized clinical trials of hyperglycemia correction in acute
myocardial infarction have been reported [22–24]. Only the first trial
showed significant benefit from aggressive insulin treatment [23]. In that
trial, the mean glucose levels were 38 mg/dL lower in the aggressive-treat-
ment group than in the control group, and mortality at 1 year (18.6%)
was significantly reduced versus the control group (26.1%). In the two later
randomized trials, the mean glucose differences between the treatment
groups were smaller (12–16 mg/dL), which may have contributed to a
neutral (no benefit) result.
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rection during coronary artery bypass surgery [25,26]. The smaller trial (N=
141), in patients with diabetes mellitus and with a mean blood glucose dif-
ference between the two treatment groups of 122 mg/dL, showed a benefit
related to the aggressive intervention [26]. However, the larger trial (N=
400), in patients mostly without diabetes and with a mean glucose difference
between the two treatment groups of 43 mg/dL, did not show a benefit [25].
These nonstroke illnesses involve considerably different pathophysiologic
processes than acute brain ischemia and therefore are not comparable to
stroke. The effects of hyperglycemia on acutely ischemic myocardium are
likely to be much different than its effects on acutely ischemic brain cells. Al-
so, much of the benefit from aggressive hyperglycemia reduction in the SICU
trial could be attributed to reductions in critical-illness polyneuropathy and
bloodstream infections, which are not applicable to most patients with acute
stroke.
Observational acute stroke hyperglycemia studies
Human studies have largely been observational, and most of them show an
association between hyperglycemia and inferior clinical outcomes from acute
ischemic stroke [10,27￿,28,29]. The higher the glucose level during acute is-
chemic stroke, the worse the outcomes are. Some studies suggest a linear de-
crease in favorable outcomes as blood glucose increases [30,31]. One study
found that during the initial 48 h of acute ischemic stroke, maximum glucose
of 155 mg/dL was the best cutoff for predicting outcome [32]. In that study,
however, the area under the receiver operating characteristic curve was only
0.66 (closer to 0.5 than to 1.0), indicating that this is not a distinct cutoff.
Some findings suggest that patients with acute lacunar strokes (small subcor-
tical infarcts caused by occlusion of small penetrating arterioles) have better
outcomes with hyperglycemia [30,33￿]. This result may be important and
deserves further study.
One study analyzed the relation between acute hyperglycemia and recan-
alization in 139 patients with MCA occlusion treated with intravenous tissue-
type plasminogen activator (tPA) [34]. The MCA occlusion was documented
and followed with transcranial Doppler. After adjusting for stroke etiology
and risk factors, poor recanalization was associated with admission hypergly-
cemia (9158 mg/dL, P=0.03), proximal MCA occlusion (P=0.03), and plate-
let count greater than 219,000/mL (P= 0 . 0 3 ) .H o w e v e r ,c h r o n i c
hyperglycemia determined by hemoglobin A1C and fructosamine had no re-
lation to recanalization. The investigators attributed the decreased recanaliza-
tion associated with hyperglycemia to antifibrinolytic and hypercoagulable
effects of hyperglycemia. The favored explanation was that glycation of the
regulatory protein annexin II increases the formation of plasminogen/tPA/
annexin complexes, which interfere with fibrinolysis. The investigators also
considered that hyperglycemia increases plasminogen activator–inhibitor
concentrations.
We studied the relation between admission hyperglycemia and recanali-
zation in 53 consecutive patients with proximal MCA occlusion treated with
endovascular procedures by the University of California at Los Angeles
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by the Thrombolysis In Myocardial Infarction (TIMI) method: poor (no or in-
complete poststenotic arterial filling, TIMI 0–1) or adequate (slow, but com-
plete, or normal poststenotic arterial filling, TIMI 2–3) using serial magnetic
resonance arteriograms. Patients with poor recanalization had somewhat
higher admission blood glucose (154 vs 139 mg/dL; P=0.66, Mann-Whitney
test) and a higher rate of hyperglycemia (9140 mg/dL) (44% vs 23%;
P=0.10, chi-square test) than patients with adequate recanalization. Our find-
ings are consistent with the previous similar studies; our sample size is likely
too small to show statistical significance.
Another important observation is the association between hyperglycemia
and hemorrhagic transformation of infarcts. Patients with higher admission
glucose levels are more likely to have a hemorrhagic conversion of their in-
farct [29,31,35,36]. We studied the relation between hyperglycemia and seri-
ous hemorrhagic transformation of infarcts in the same 53 consecutive
patients just discussed. Serious hemorrhagic transformation was determined
by serial MRI as confluent parenchymal hemorrhage with some mass effect
within 24 h after stroke onset. Patients with serious hemorrhagic transforma-
tion had somewhat higher admission glucose levels (159 versus 140 mg/dL;
P=0.19, Mann-Whitney test) and a higher rate of hyperglycemia (9140 mg/
dL) (50% vs 24%; P=0.09, chi-square test) than patients without serious
hemorrhagic transformation. This finding is also consistent with previously
published observations in patients treated with thrombolysis, and this com-
plication also has been reported in animal studies [37,38].
In addition to clinical outcomes, there is MRI evidence of ischemic stroke
worsening with hyperglycemia [39–42]. Higher blood glucose levels have
been associated with greater acute infarct growth compared with lower glu-
cose levels, based on acute and delayed diffusion and perfusion MRI. How-
ever, one study found that in a small subgroup (N=11) of acute stroke
patients with persistent arterial occlusion, treatment of hyperglycemia with
intravenous insulin was associated with greater infarct growth [43]. Addition-
al studies are needed to clarify these interesting observations.
How might hyperglycemia exacerbate ischemic brain injury?
The reproducible associations reported between hyperglycemia and poorer
outcomes suggest a potential causal relationship. Multiple physiologic mech-
anisms have been proposed for how hyperglycemia might exacerbate ische-
mic brain injury (Table 1). The relative importance of the various injury-
exacerbating mechanisms has not been established.
Much attention has been devoted to the study of brain lactate accumula-
tion and brain acidosis due to hyperglycemia, but lactate has not been shown
to exacerbate acute ischemic brain injury in animal studies [27￿] or in a pilot
clinical stroke trial [43].
Another potential mechanism by which hyperglycemia may exacerbate is-
chemic brain injury occurs at the level of microcirculation. Hyperglycemia
can induce a variety of detrimental changes in cerebral endothelial cells with-
in hours [13]. Acute hyperglycemia can impair cerebrovascular autoregula-
tion, resulting in deleterious reperfusion predisposing to hemorrhagic
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through nuclear factor kappa-light-chain-enhancer of activated B cells
(NF-κB), leading to upregulation of intracellular adhesion molecule 1, vascu-
lar cellular adhesion molecule 1, and E-selectin [13]. The adhesion molecules
promote leukocyte adhesion to post-capillary venule walls, obstructing flow
[44].
Hyperglycemia can also increase levels of plasminogen activator inhibitor
1 (PAI-1) by post-translational modification of proteins [13]. PAI-1 interferes
with the actions of tPA, reducing the chance of early brain reperfusion. Another
apparently important exacerbating mechanism of acute ischemic brain injury
with hyperglycemia is the accumulation of free radicals. One study showed
that glucose donates electrons to form superoxide radicals that exacerbate
the injury during acute brain ischemia [45].
Randomized clinical trials in acute stroke with hyperglycemia
The supporting data outlined above have inspired five randomized pilot clin-
ical trials of rapid hyperglycemia correction in acute ischemic stroke [43,46–
49]. These pilot trials have demonstrated the relative safety and feasibility of
rapid hyperglycemia lowering with intravenous insulin as compared with
subcutaneous insulin during acute stroke. These small pilot trials were not
intended to show clinical efficacy of the intravenous insulin intervention.
One efficacy trial in acute stroke with hyperglycemia has been completed,
the GIST-UK (Glucose Insulin Stroke Trial—United Kingdom) [50￿, Class I].
In this trial, 933 acute stroke patients without previous insulin treatment
were randomized within 24 h after stroke onset to infusions of normal saline
or insulin for 24 h. The mean admission glucose level was similar in the two
treatment groups (137–141 mg/dL), and during treatment the difference in
mean glucose between the two groups was only 10 mg/dL. The only worri-
some complication was an increase in mortality associated with the largest
drops in blood glucose levels in the insulin-treated group. There were no sig-
nificant differences in clinical outcomes, including mortality, neurologic def-
Table 1. Derangements exacerbated by hyperglycemia during brain ischemia in animal studies, clinical
studies, or both
a
Brain acidosis and increased lactate
Cytotoxic brain edema
Hemorrhagic transformation of infarcts
Impaired thrombolysis
Blood-brain barrier disruption
Cytotoxicity, slowed calcium recovery
Impaired ATP/energy recovery
Accumulation of free radicals
Impaired vascular reactivity
Stimulated inflammatory reactions
aThe relative importance of these derangements has not been established
ATP—adenosine triphosphate
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sion and hyperglycemia lowering may not be beneficial during acute stroke,
additional potential reasons for the neutral results of the GIST-UK trial in-
clude delayed initiation of insulin infusion and the relatively small difference
in glucose levels between the treatment groups.
Additional clinical efficacy trials are needed to address the uncertainty
about the benefit of rapid hyperglycemia correction during acute stroke.
These trials should differ from the GIST-UK trial by initiating the insulin in-
fusion sooner and enrolling patients with higher glucose levels to achieve a
greater difference in glucose between the treatment groups. If proven benefi-
cial, a substantial proportion of acute stroke patients could be treated more
effectively with a relatively inexpensive drug (insulin) that is familiar to
health care providers. If this treatment proves ineffective, our efforts can be
redirected toward other promising acute stroke therapies.
Another reason why additional randomized clinical trials are needed
involves the costs of the treatment. Using intravenous insulin to rapidly con-
trol hyperglycemia (near 100 mg/dL) during acute illness requires admission
to a specialized hospital unit that is prepared to administer it—either an ICU
or, in some hospitals, an intermediate unit (also termed a transitional, pro-
gressive, or stepdown unit). Consequently, safe intravenous insulin infusion
therapy necessitates a greater personnel effort and eventually greater cost. To
justify such additional effort, costs, and risk, we should await convincing ev-
idence of efficacy from randomized clinical trials.
Treatment
Lowering hyperglycemia during acute stroke
Subcutaneous insulin
Subcutaneous insulin protocols usually can maintain blood glucose
levels below 200 mg/dL in most patients, especially if basal insulin is
added.
Subcutaneous regular insulin sliding scales are familiar to health care
providers and seem safe because they typically lower blood glucose levels
over a period of several hours and rarely result in hypoglycemia. The
most simple sliding scales call for regular insulin doses based on the
recent glucose levels.
More sophisticated treatment protocols include additional insulin
doses for meals and long-acting basal insulin [51]. When available, an
endocrinology consultant can optimize the acute treatment and help the
transition to long-term care.
Daily insulin needs are likely to change rapidly during acute illness.
The subcutaneous insulin sliding scales do not require admission to
specialized hospital units or frequent glucose monitoring and appear to
be the current standard of care in most clinical settings. However, it
seems unreasonable that subcutaneous insulin treatment will rapidly
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good control during acute stroke.
Intravenous insulin
At this time, the only effective method to lower hyperglycemia to near
100 mg/dL within 4 to 5 h and to keep it near that level is to use in-
travenous insulin.
For ischemic stroke treated with thrombolytic drugs, it may be best to
rapidly lower severe hyperglycemia. For example, if the admission blood
glucose is approximately 300 mg/dL and the patient is a candidate for
thrombolytic therapy, consider giving an intravenous bolus of regular
insulin 8 units. Somewhat lower or higher insulin doses may be best for
lesser or greater hyperglycemia. This bolus will start lowering the blood
glucose in about 5 min. A temporary continuous intravenous insulin
infusion may then be used in most patients to maintain the glucose
closer to normal levels (eg, below 180 or 140 mg/dL).
There are multiple protocols that rapidly correct hyperglycemia in ICU
patients. Some protocols have trade names [52,53] and some do not [46].
Some academic institutions use protocols developed by local experts; some
of these are available on their institutional websites, and many are publicly
accessibleontheWeb[54].Differencesbetweentheseprotocolsthatdonot
appear to becrucial atthis timeinclude whether to add potassium and/or a
small amount of glucose to the solution. These protocols consider recent
bloodglucoselevelsbutdiffersomewhatintheformulasusedtodetermine
the exact increases and decreases in insulin infusion rates over time. Such
protocols have not been compared in head-to-head trials. They appear to
havesimilarglucose-loweringefficiencyandlowriskofclinicallysignificant
hypoglycemia (G40 mg/dL). Computerized protocols are likely superior to
paper-based protocols because they eliminate human error in calculating
the infusion rate adjustments, they facilitate accurate data storage, and they
have built-in reminders to recheck glucose levels.
Rapid and safe hyperglycemia correction requires glucose monitoring
every 1 to 2 h. Capillary, venous, or arterial glucose measurements differ
somewhat in a consistent fashion over a large range of levels, but all are
considered appropriate and reliable for monitoring. Transdermal and sub-
cutaneous glucose sensing devices are also available, but they reflect the
blood glucose with 15 to 30 min delay and thus should be supplemented
with blood measurements when the blood glucose levels are dropping rap-
idly. Computerized programs for storing and tracking the glucose levels over
time are ideal because they can show the results in a useful output rapidly.
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